AI Maverick Intel Inc. (OTC: AIMV) has taken a significant step toward its proposed acquisition of HEAL Access Canada Inc. by issuing 76.5 million common shares to HEAL Group Holdings. This issuance represents the initial tranche of consideration under the Right of First Refusal Agreement dated February 11, 2026, between the two companies. The total consideration for the transaction has been adjusted from 120 million to 100 million AIMV common shares, and the parties are continuing to work toward a definitive agreement.
The move signals AI Maverick's commitment to expanding its footprint in the healthcare and data platform sectors. HEAL Access Canada is expected to bring complementary capabilities to AI Maverick's portfolio, which focuses on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The company evaluates strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value.
In addition to the acquisition progress, AI Maverick announced plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy. An uplisting to the OTCQB could enhance the company's visibility and liquidity, potentially attracting a wider range of institutional and retail investors. This move aligns with the company's goal of building a strong public market presence and supporting its growth initiatives.
The adjustment of the total consideration from 120 million to 100 million shares reflects ongoing negotiations and due diligence. The issuance of the initial 76.5 million shares demonstrates the parties' commitment to moving forward with the transaction. For investors, this development provides clarity on the valuation and structure of the deal, which could impact the company's share count and future earnings potential.
AI Maverick Intel Inc. is a company focused on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The company evaluates strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value. The proposed acquisition of HEAL Access Canada aligns with this strategy, as HEAL Access is likely to bring expertise in healthcare data and access solutions.
The announcement also highlights the broader trend of AI companies seeking to integrate healthcare data platforms. As artificial intelligence continues to transform industries, the ability to access and analyze healthcare data becomes increasingly valuable. AI Maverick's acquisition of HEAL Access Canada could position the company to capitalize on this trend, potentially offering innovative solutions for healthcare providers and patients.
For the industry, this transaction underscores the growing convergence of AI and healthcare. Companies that can effectively combine AI capabilities with domain-specific data are likely to gain a competitive edge. AI Maverick's strategic focus on scalable platforms and acquisitions suggests a long-term vision for building a diversified technology portfolio.
Investors should monitor the progress toward a definitive agreement and the completion of the OTCQB uplisting. The issuance of initial shares and the adjusted consideration provide a clearer picture of the transaction's terms. As the company moves forward, further updates on the acquisition and capital markets strategy are expected.
For more information on AI Maverick Intel Inc., visit the company's newsroom at http://ibn.fm/AIMV. The full press release is available at https://ibn.fm/mivWz.
